Introduction
Because serum cholesterol level is strongly associated with coronary heart disease, it has been generally assumed that cholesterol reduction by statins is the predominant, if not the only, mechanism underlying their beneficial effects. Data from a meta-analysis of lipid-lowering trials suggest lipid modification alone accounts for the clinical benefits associated with statin therapy. Indeed, the slope of the relationship between cholesterol reduction and mortality risk reduction was the same for statins and nonstatins, whereas the mortality risk reductions realized over statin treatment periods of 2 years and longer were found to be a consequence of cholesterol reduction alone. However, this type of meta-analysis does not take into account the differences in terms of the length of the individual trials with respect to cardiovascular benefits. Some of the nonstatin lipid-lowering trials, such as the Lipid Research Clinic Coronary Primary Prevention Trial (LRC-CPPT) [1] using the bile acid resin cholestyramine, or the Program on the Surgical Control of the Hyperlipidemias (POSCH) [2] using partial ileal bypass surgery, reported benefits after 7.4 and 9.7 years, respectively, whereas most statin trials showed benefits at much earlier time-points (eg, within 5 years). Thus, if one compares the benefits after 5 years for all lipid-lowering trials, one finds that the nonstatin trials no longer fall on the same slope of cholesterol-mortality risk reduction as do all of the statin trials. In fact, the benefits of cholesterol lowering after ileal bypass surgery in the POSCH study were not realized at 4.5 years, despite significant low-density lipoprotein cholesterol (LDL-C) reduction of 34% within the first 3 months after the surgical procedure. These results suggest that the beneficial effects of statins occur more rapidly and may not be entirely dependent on cholesterol reduction.
Rationale for Statin Pleiotropy in Clinical Trials
In the recent Heart Protection Study (HPS) [3] and Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) [4] , the relative risk reduction conferred by statin treatment was independent of the pretreatment lipid levels. These large prospective trials raise the question of whether individuals with CHD could benefit from statin drugs independently of cholesterol levels. In agreement with these observations, subgroup analyses of previous clinical trials suggested that the beneficial effects of statins could extend to mechanisms beyond cholesterol reduction. For example, subgroup analysis of the West of Scotland Coronary Prevention (WOSCOP) study [5] and the Cholesterol And Recurrent Events (CARE) study [6] indicates that despite comparable serum cholesterol levels among the statin-treated and placebo groups, statin-treated individuals have significantly lower risks for coronary heart disease compared with age-matched Does It Matter Whether or Not a Lipid-lowering Agent Inhibits Rho Kinase?
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and placebo-controlled individuals. Indeed, when the statin-treatment group was divided into quintiles of percentage LDL-C reduction, it was found that there was no difference in the 4.4-year coronary event rate for quintiles 2 through 5 (LDL-C reductions of 23%-41%). Hence, there was no apparent association between coronary event rate and the level of LDL-C reduction. Furthermore, meta-analyses of cholesterol-lowering trials suggest that the risk of myocardial infarction in individuals treated with statins is significantly lower compared with individuals treated with other cholesterol-lowering agents or modalities despite comparable reduction in serum cholesterol levels in both groups [7] . For example, application of the Framingham Risk Score to WOSCOPS produced a coincidence between predicted and observed risk in the placebo group but underestimated the benefit of the pravastatin group by 31% [8].
Rationale for No Statin Pleiotropy in Clinical Trials
Despite the rapidity of benefits of statin therapy compared with other nonstatin lipid-lowering therapies, it is still difficult to prove that pleiotropic effects of statins are real. First, patients receiving statin therapy invariably will have reduced lipid levels, and it is often difficult to separate the lipid-lowering from the non-lipid-lowering effects of statins in clinical trials. Second, many effects of statins, such as improvement in endothelial function, decreased inflammation, increased plaque stability, and reduced thrombogenic response, could all be accounted for, to some extent, by lipid lowering. Third, the concentrations used to demonstrate the biologic effects of statins in cell culture and animal experiments, especially in regard to inhibition of Rho geranylgeranylation but not PI3-kinase/ Akt activation, appear to be much higher than what is prescribed clinically. Finally, both hydrophilic and lipophilic statins, which inhibit hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, appear to exert similar cholesterol-independent effects despite the relative impermeability of hydrophilic statins in vascular tissues.
Thus, it appears that lipid lowering contributes to many of the clinical benefits of statin therapy. Finally, the lipophilic statins would be expected to penetrate cell membranes more effectively than the more hydrophilic statins, causing more side effects, but at the same time eliciting more pleiotropic effects. However, the observation that hydrophilic statins have similar pleiotropic effects as lipophilic statins puts into question whether there are really any cholesterol-independent effects of statins. Indeed, recent evidence suggests that some of the cholesterol-independent effects of these agents may be mediated by inhibition of hepatic HMG CoA reductase, leading to subsequent reduction in circulating isoprenoid levels [9] . This hypothesis may help explain why hydrophilic statins such as pravastatin and rosuvastatin are still able to exert cholesterol-independent benefits on the vascular wall without directly entering vascular wall cells. In this respect, the word "pleiotropic" probably does not reflect the hepatic versus nonhepatic effects of these agents.
Statins and Isoprenylated Proteins
By inhibiting L-mevalonic acid synthesis, statins also prevent the synthesis of other important isoprenoid intermediates of the cholesterol biosynthetic pathway, such as farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) [10] . These intermediates serve as important lipid attachments for the post-translational modification of a variety of proteins, including the subunit of heterotrimeric G-proteins, Heme-a, nuclear lamins, and the small guanosine triphosphate-binding protein Ras and Ras-like proteins such as Rho, Rab, Rac, Ral, or Rap [11] . Thus, protein isoprenylation permits the covalent attachment, subcellular localization, and intracellular trafficking of membrane-associated proteins. Members of the Ras and Rho GTPase family are major substrates for post-translational modification by prenylation [11, 12] . By virtue of inhibiting isoprenoid synthesis, statins inhibit both Ras and Rho function in hepatic and peripheral tissues.
Because Rho is major target of geranylgeranylation, inhibition of Rho and its downstream target, Rho kinase (ROCK), is a likely mechanism mediating some of the pleiotropic effects of statins on the vascular wall [13, 14] . Each member of the Rho family serves specific functions in terms of cell shape, motility, secretion, and proliferation, although overlapping functions between the members could be observed in over-expressed systems. The activation of Rho in Swiss 3T3 fibroblasts by extracellular ligands, such as platelet-derived lysophosphatidic acid, leads to myosin light chain phosphorylation and formation of focal adhesion complexes [11, 12, 15] . Indeed, ROCK increases the sensitivity of vascular smooth muscle to calcium in hypertension [16] and coronary spasm [17] . In contrast, activation of Rac leads to the formation of lamellipodia, membrane ruffles, and oxidative stress, whereas activation of Cdc42 induces actin-rich surface protrusions called filopodia.
Role of ROCK in Cardiovascular Disease
There is growing evidence that abnormal ROCK function contributes to cardiovascular disease [18] . In the vascular wall, ROCK mediates vascular smooth muscle contraction, actin cytoskeleton organization, cell adhesion, and motility [19] . Thus, abnormal ROCK activity may contribute to abnormal smooth muscle contraction observed in cerebral and coronary vasospasm [20, 21] , hypertension [22] , and pulmonary hypertension [23] . In addition, ROCK could also regulate vascular tone and blood flow indirectly through negative effects on endothelial nitric oxide synthase (eNOS) expression and activity
